EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSVPAG00000001506
Gene Symbol: DHCR24
1 Cross references
208 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSVPAG00000009376
Gene Symbol: HMGCR
1 Cross references
270 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSVPAG00000001059
Gene Symbol: NT5E
1 Cross references
249 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSVPAG00000009454
Gene Symbol: HTR2A
1 Cross references
217 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSVPAG00000001869
Gene Symbol: HTR2B
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSVPAG00000012283
Gene Symbol: HTR2C
1 Cross references
222 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSVPAG00000003489
Gene Symbol: HTR3B
1 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSVPAG00000000388
Gene Symbol: HTR4
1 Cross references
200 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSVPAG00000005500
Gene Symbol: ARAF
1 Cross references
190 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSVPAG00000008045
Gene Symbol: ADAM17
1 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSVPAG00000004590
Gene Symbol: ADAMTS5
1 Cross references
200 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSVPAG00000003098
Gene Symbol: AKT3
1 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).